Department of Oncology and Bio-therapeutic Center, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen Research Center for Communicable Disease Diagnosis and Treatment, Shenzhen, 518112, China.
Department of Oncology, The First Medical Center, General Hospital of PLA, Beijing, 100853, China.
Cell Death Dis. 2022 Apr 11;13(4):330. doi: 10.1038/s41419-022-04718-8.
Risk of metastasis is increased by the presence of chromosome 3 monosomy in uveal melanoma (UM). This study aimed to identify more accurate biomarker for risk of metastasis in UM. A total of 80 patients with UM from TCGA were assigned to two groups based on the metastatic status, and bioinformatic analyses were performed to search for critical genes for risk of metastasis. SLC25A38, located on chromosome 3, was the dominant downregulated gene in metastatic UM patients. Low expression of SLC25A38 was an independent predictive and prognostic factor in UM. The predictive potential of SLC25A38 expression was superior to that of pervious reported biomarkers in both TCGA cohort and GSE22138 cohort. Subsequently, its role in promoting metastasis was explored in vitro and in vivo. Knock-out of SLC25A38 could enhance the migration ability of UM cells, and promote distant metastasis in mice models. Through the inhibition of CBP/HIF-mediated pathway followed by the suppression of pro-angiogenic factors, SLC25A38 was situated upstream of metastasis-related pathways, especially angiogenesis. Low expression of SLC25A38 promotes angiogenesis and metastasis, and identifies increased metastatic risk and worse survival in UM patients. This finding may further improve the accuracy of prognostic prediction for UM.
染色体 3 单体性增加了葡萄膜黑色素瘤(UM)的转移风险。本研究旨在寻找 UM 转移风险更准确的生物标志物。从 TCGA 中选取 80 名 UM 患者,根据转移状态将其分为两组,并进行生物信息学分析,以寻找与转移风险相关的关键基因。位于染色体 3 上的 SLC25A38 是转移性 UM 患者中下调最明显的基因。SLC25A38 的低表达是 UM 的独立预测和预后因素。SLC25A38 表达的预测潜力在 TCGA 队列和 GSE22138 队列中均优于先前报道的生物标志物。随后,在体外和体内探索了其促进转移的作用。敲除 SLC25A38 可增强 UM 细胞的迁移能力,并促进小鼠模型中的远处转移。通过抑制 CBP/HIF 介导的通路,抑制促血管生成因子,SLC25A38 位于转移相关通路的上游,特别是血管生成。SLC25A38 的低表达促进血管生成和转移,并确定 UM 患者的转移风险增加和生存状况较差。这一发现可能进一步提高 UM 预后预测的准确性。